Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
Francis Grand, Claire Hidalgo-Curtis, Thomas Ernst, et al.
Blood (2009) Vol. 113, Iss. 24, pp. 6182-6192
Open Access | Times Cited: 366

Showing 1-25 of 366 citing articles:

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl, Heinz Gisslinger, Ashot S. Harutyunyan, et al.
New England Journal of Medicine (2013) Vol. 369, Iss. 25, pp. 2379-2390
Open Access | Times Cited: 1851
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil, Moritz Gerstung, Luca Malcovati, et al.
Blood (2013) Vol. 122, Iss. 22, pp. 3616-3627
Open Access | Times Cited: 1711
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar, Kristen E. Stevenson, Omar Abdel‐Wahab, et al.
New England Journal of Medicine (2011) Vol. 364, Iss. 26, pp. 2496-2506
Open Access | Times Cited: 1557
SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts
Elli Papaemmanuil, Mario Cazzola, Jacqueline Boultwood, et al.
New England Journal of Medicine (2011) Vol. 365, Iss. 15, pp. 1384-1395
Open Access | Times Cited: 1162
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Thomas Ernst, Andrew Chase, Joannah Score, et al.
Nature Genetics (2010) Vol. 42, Iss. 8, pp. 722-726
Closed Access | Times Cited: 1108
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi, T L Lasho, Paola Guglielmelli, et al.
Leukemia (2013) Vol. 27, Iss. 9, pp. 1861-1869
Closed Access | Times Cited: 717
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker, Róbert Královics
Blood (2016) Vol. 129, Iss. 6, pp. 667-679
Open Access | Times Cited: 531
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
Ayalew Tefferi
Leukemia (2010) Vol. 24, Iss. 6, pp. 1128-1138
Open Access | Times Cited: 517
JAK/STAT signaling in hematological malignancies
William Vainchenker, Stefan N. Constantinescu
Oncogene (2012) Vol. 32, Iss. 21, pp. 2601-2613
Open Access | Times Cited: 477
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani, Jason Gotlib, Catriona Jamieson, et al.
Journal of Clinical Oncology (2011) Vol. 29, Iss. 7, pp. 789-796
Open Access | Times Cited: 397
New mutations and pathogenesis of myeloproliferative neoplasms
William Vainchenker, François Delhommeau, Stefan N. Constantinescu, et al.
Blood (2011) Vol. 118, Iss. 7, pp. 1723-1735
Open Access | Times Cited: 394
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
Rocco Piazza, Simona Valletta, Nils Winkelmann, et al.
Nature Genetics (2012) Vol. 45, Iss. 1, pp. 18-24
Open Access | Times Cited: 382
RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis
Stanley Lipkowitz, Allan M. Weissman
Nature reviews. Cancer (2011) Vol. 11, Iss. 9, pp. 629-643
Open Access | Times Cited: 371
Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia
Charlotte M. Niemeyer, Michelle Kang, Danielle H. Shin, et al.
Nature Genetics (2010) Vol. 42, Iss. 9, pp. 794-800
Open Access | Times Cited: 351
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Ayalew Tefferi, William Vainchenker
Journal of Clinical Oncology (2011) Vol. 29, Iss. 5, pp. 573-582
Closed Access | Times Cited: 318
Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A
A. Jankowska, Hideki Makishima, Ramón V. Tiu, et al.
Blood (2011) Vol. 118, Iss. 14, pp. 3932-3941
Open Access | Times Cited: 317
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
Ayalew Tefferi, Terra L. Lasho, Omar Abdel‐Wahab, et al.
Leukemia (2010) Vol. 24, Iss. 7, pp. 1302-1309
Open Access | Times Cited: 310
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
Alexander Kohlmann, Vera Großmann, Hans‐Ulrich Klein, et al.
Journal of Clinical Oncology (2010) Vol. 28, Iss. 24, pp. 3858-3865
Closed Access | Times Cited: 288
SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML)
Manja Meggendorfer, Andreas Roller, Torsten Haferlach, et al.
Blood (2012) Vol. 120, Iss. 15, pp. 3080-3088
Open Access | Times Cited: 287
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Jorge E. Cortés, et al.
Nature Reviews Drug Discovery (2011) Vol. 10, Iss. 2, pp. 127-140
Closed Access | Times Cited: 284
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
Mignon L. Loh, Debbie S. Sakai, Christian Flotho, et al.
Blood (2009) Vol. 114, Iss. 9, pp. 1859-1863
Open Access | Times Cited: 283
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli, Flavia Biamonte, Joannah Score, et al.
Blood (2011) Vol. 118, Iss. 19, pp. 5227-5234
Open Access | Times Cited: 256
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra, Harini Nivarthi, Heinz Gisslinger, et al.
Blood (2015) Vol. 127, Iss. 3, pp. 325-332
Open Access | Times Cited: 255
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
Shannon Elf, Nouran S. Abdelfattah, Edwin Chen, et al.
Cancer Discovery (2016) Vol. 6, Iss. 4, pp. 368-381
Open Access | Times Cited: 247
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms
David A. Hinds, Kimberly E. Barnholt, Ruben A. Mesa, et al.
Blood (2016) Vol. 128, Iss. 8, pp. 1121-1128
Open Access | Times Cited: 216
Page 1 - Next Page

Scroll to top